XILIS, Inc.

Cancer is the second leading cause of death in the U.S. and metastatic disease remains predominantly incurable. New cancer cases and healthcare costs continue to increase year-over-year. Precision medicine aims to select the most effective treatments for patients, but existing approaches only benefit a minority of patients. Xilis is developing next generation MicroOrganoSphere technologies to guide precision therapy for cancer patients and accelerate drug discovery.